Growth and metastasis of B16-F10 melanoma cells is not critically dependent on host CD73 expression in mice

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Burghoff, Sandra ^a,c   Gong, Xuan ^a   Viethen, Claudia ^a   Jacoby, Christoph ^a   Flögel, Ulrich ^a   Bongardt, Sabine ^a   Schorr, Anne ^b   Hippe, Andreas ^b   Homey, Bernhard ^b   Schrader, Jürgen ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^c MVZ Labor Dessau GmbH   (Germany)

Author keywords

Adenosine; B16 F10 melanoma; CD73; Immune system; Mice; Tumor

Indexed keywords

5' NUCLEOTIDASE; ALKALINE PHOSPHATASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER GROWTH; CELL SUBPOPULATION; CONTROLLED STUDY; FEMALE; HEMATOPOIETIC CELL; IMMUNOCOMPETENT CELL; LUNG METASTASIS; MALE; MELANOMA B16 F10; MELANOMA CELL; METASTASIS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; ANIMAL; BIOSYNTHESIS; EXPERIMENTAL MELANOMA; GENETICS; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

5'-NUCLEOTIDASE; ANIMALS; CELL LINE, TUMOR; FEMALE; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, KNOCKOUT;

EID: 84924373634     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-898     Document Type: Article

References (44)

1. Stagg J, Smyth MJ: Extracellular adenosine triphosphate and adenosine in cancer. Oncogene 2010, 29:5346-5358. 10.1038/onc.2010.292
2. Berglund E, Berglund D, Akcakaya P, Ghaderi M, Daré E, Berggren P, Köhler M, Aspinwall CA, Lui W, Zedenius J, Larsson C, Bränström R: Evidence for Ca(2+)-regulated ATP release in gastrointestinal stromal tumors. Exp Cell Res 2013, 319:1229-1238. 10.1016/j.yexcr.2013.03.001
3. Ayna G, Krysko DV, Kaczmarek A, Petrovski G, Vandenabeele P, Fésüs L: ATP release from dying autophagic cells and their phagocytosis are crucial for inflammasome activation in macrophages. PLoS One 2012, 7:e40069. 10.1371/journal.pone.0040069
4. Antonioli L, Blandizzi C, Pacher P, Haskó G: Immunity, inflammation and cancer: a leading role for adenosine. Nat Rev Cancer 2013, 13:842-857. 10.1038/nrc3613
5. Allard B, Turcotte M, Stagg J: CD73-generated adenosine: orchestrating the tumor-stroma interplay to promote cancer growth. J Biomed Biotechnol 2012, 2012:485156.
6. Ohta A, Gorelik E, Prasad SJ, Ronchese F, Lukashev D, Wong MK, Huang X, Caldwell S, Liu K, Smith P, Chen J, Jackson EK, Apasov S, Abrams S, Sitkovsky M: A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci U S A 2006, 103:13132-13137. 10.1073/pnas.0605251103
7. Ryzhov S, Novitskiy SV, Zaynagetdinov R, Goldstein AE, Carbone DP, Biaggioni I, Dikov MM, Feoktistov I: Host A(2B) adenosine receptors promote carcinoma growth. Neoplasia 2008, 10:987-995.
8. Synowitz M, Glass R, Färber K, Markovic D, Kronenberg G, Herrmann K, Schnermann J, Nolte C, van Rooijen N, Kiwit J, Kettenmann H: A1 adenosine receptors in microglia control glioblastoma-host interaction. Cancer Res 2006, 66:8550-8557. 10.1158/0008-5472.CAN-06-0365
9. Morello S, Sorrentino R, Montinaro A, Luciano A, Maiolino P, Ngkelo A, Arra C, Adcock IM, Pinto A: NK1.1 cells and CD8 T cells mediate the antitumor activity of Cl-IB-MECA in a mouse melanoma model. Neoplasia 2011, 13:365-373.
10. Beavis PA, Divisekera U, Paget C, Chow MT, John LB, Devaud C, Dwyer K, Stagg J, Smyth MJ, Darcy PK: Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors. Proc Natl Acad Sci U S A 2013, 110:14711-14716. 10.1073/pnas.1308209110
11. Sadej R, Skladanowski AC: Dual, enzymatic and non-enzymatic, function of ecto-5'-nucleotidase (eN, CD73) in migration and invasion of A375 melanoma cells. Acta Biochim Pol 2012, 59:647-652.
12. Stagg J, Divisekera U, McLaughlin N, Sharkey J, Pommey S, Denoyer D, Dwyer KM, Smyth MJ: Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc Natl Acad Sci U S A 2010, 107:1547-1552. 10.1073/pnas.0908801107
13. Koszałka P, Pryszlak A, Gołuńska M, Kolasa J, Stasiłojć G, Składanowski AC, Bigda JJ: Inhibition of CD73 stimulates the migration and invasion of B16F10 melanoma cells in vitro, but results in impaired angiogenesis and reduced melanoma growth in vivo. Oncol Rep 2014, 31:819-827.
14. Stagg J, Divisekera U, Duret H, Sparwasser T, Teng MW, Darcy PK, Smyth MJ: CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. Cancer Res 2011, 71:2892-2900. 10.1158/0008-5472.CAN-10-4246
15. Wang L, Fan J, Thompson LF, Zhang Y, Shin T, Curiel TJ, Zhang B: CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice. J Clin Invest 2011, 121:2371-2382. 10.1172/JCI45559
16. Yegutkin GG, Marttila-Ichihara F, Karikoski M, Niemelä J, Laurila JP, Elima K, Jalkanen S, Salmi M: Altered purinergic signaling in CD73-deficient mice inhibits tumor progression. Eur J Immunol 2011, 41:1231-1241. 10.1002/eji.201041292
17. Forte G, Sorrentino R, Montinaro A, Luciano A, Adcock IM, Maiolino P, Arra C, Cicala C, Pinto A, Morello S: Inhibition of CD73 improves B cell-mediated anti-tumor immunity in a mouse model of melanoma. J Immunol 2012, 189:2226-2233. 10.4049/jimmunol.1200744
18. Leth-Larsen R, Lund R, Hansen HV, Laenkholm A, Tarin D, Jensen ON, Ditzel HJ: Metastasis-related plasma membrane proteins of human breast cancer cells identified by comparative quantitative mass spectrometry. Mol Cell Proteomics 2009, 8:1436-1449. 10.1074/mcp. M800061-MCP200
19. Supernat A, Markiewicz A, Welnicka-Jaskiewicz M, Seroczynska B, Skokowski J, Sejda A, Szade J, Czapiewski P, Biernat W, Zaczek A: CD73 expression as a potential marker of good prognosis in breast carcinoma. Appl Immunohistochem Mol Morphol 2012, 20:103-107. 10.1097/PAI.0b013e3182311d82
20. Pivarcsi A, Müller A, Hippe A, Rieker J, van Lierop A, Steinhoff M, Seeliger S, Kubitza R, Pippirs U, Meller S, Gerber PA, Liersch R, Buenemann E, Sonkoly E, Wiesner U, Hoffmann TK, Schneider L, Piekorz R, Enderlein E, Reifenberger J, Rohr U, Haas R, Boukamp P, Haase I, Nürnberg B, Ruzicka T, Zlotnik A, Homey B: Tumor immune escape by the loss of homeostatic chemokine expression. Proc Natl Acad Sci U S A 2007, 104:19055-19060. 10.1073/pnas.0705673104
21. Raz A, McLellan WL, Hart IR, Bucana CD, Hoyer LC, Sela BA, Dragsten P, Fidler IJ: Cell surface properties of B16 melanoma variants with differing metastatic potential. Cancer Res 1980, 40:1645-1651.
22. Koszalka P, Ozüyaman B, Huo Y, Zernecke A, Flögel U, Braun N, Buchheiser A, Decking UK, Smith ML, Sévigny J, Gear A, Weber A, Molojavyi A, Ding Z, Weber C, Ley K, Zimmermann H, Gödecke A, Schrader J: Targeted disruption of cd73/ecto-5'-nucleotidase alters thromboregulation and augments vascular inflammatory response. Circ Res 2004, 95:814-821. 10.1161/01.RES.0000144796.82787.6f
23. Kisanuki YY, Hammer RE, Miyazaki J, Williams SC, Richardson JA, Yanagisawa M: Tie2-Cre transgenic mice: a new model for endothelial cell-lineage analysis in vivo. Dev Biol 2001, 230:230-242. 10.1006/dbio.2000.0106
24. Pellegatti P, Raffaghello L, Bianchi G, Piccardi F, Pistoia V, Di Virgilio F: Increased level of extracellular ATP at tumor sites: in vivo imaging with plasma membrane luciferase. PLoS One 2008, 3:e2599. 10.1371/journal.pone.0002599
25. Madi L, Bar-Yehuda S, Barer F, Ardon E, Ochaion A, Fishman P: A3 adenosine receptor activation in melanoma cells: association between receptor fate and tumor growth inhibition. J Biol Chem 2003, 278:42121-42130. 10.1074/jbc. M301243200
26. Zigrino P, Kuhn I, Bäuerle T, Zamek J, Fox JW, Neumann S, Licht A, Schorpp-Kistner M, Angel P, Mauch C: Stromal expression of MMP-13 is required for melanoma invasion and metastasis. J Invest Dermatol 2009, 129:2686-2693. 10.1038/jid.2009.130
27. Sitkovsky M, Ohta A: Targeting the hypoxia-adenosinergic signaling pathway to improve the adoptive immunotherapy of cancer. J Mol Med 2013, 91:147-155. 10.1007/s00109-013-1001-9
28. Ghiringhelli F, Bruchard M, Chalmin F, Rébé C: Production of adenosine by ectonucleotidases: a key factor in tumor immunoescape. J Biomed Biotechnol 2012, 2012:473712.
29. Chandler CH, Chari S, Dworkin I: Does your gene need a background check? How genetic background impacts the analysis of mutations, genes, and evolution. Trends Genet 2013, 29:358-366. 10.1016/j.tig.2013.01.009
30. Harvey M, McArthur MJ, Montgomery CA, Bradley A, Donehower LA: Genetic background alters the spectrum of tumors that develop in p53-deficient mice. FASEB J 1993, 7:938-943.
31. Thompson LF, Eltzschig HK, Ibla JC, Van De Wiele CJ, Resta R, Morote-Garcia JC, Colgan SP: Crucial role for ecto-5'-nucleotidase (CD73) in vascular leakage during hypoxia. J Exp Med 2004, 200:1395-1405. 10.1084/jem.20040915
32. Baron RM, Choi AJ, Owen CA, Choi AM: Genetically manipulated mouse models of lung disease: potential and pitfalls. Am J Physiol Lung Cell Mol Physiol 2012, 302:L485-L497. 10.1152/ajplung.00085.2011
33. Chassaing B, Aitken JD, Gewirtz AT, Vijay-Kumar M: Gut microbiota drives metabolic disease in immunologically altered mice. Adv Immunol 2012, 116:93-112.
34. Hansen CH, Metzdorff SB, Hansen AK: Customizing laboratory mice by modifying gut microbiota and host immunity in an early "window of opportunity". Gut Microbes 2013, 4:241-245. 10.4161/gmic.23999
35. Ivanov II, Honda K: Intestinal commensal microbes as immune modulators. Cell Host Microbe 2012, 12:496-508. 10.1016/j.chom.2012.09.009
36. Nicklas W, Baneux P, Boot R, Decelle T, Deeny AA, Fumanelli M, Illgen-Wilcke B: Recommendations for the health monitoring of rodent and rabbit colonies in breeding and experimental units. Lab Anim 2002, 36:20-42. 10.1258/0023677021911740
37. Phillis JW, Wu PH: Adenosine may regulate the vascular supply and thus the growth and spread of neoplastic tissues: a proposal. Gen Pharmacol 1981, 12:309-310. 10.1016/0306-3623(81)90080-X
38. Böring YC, Flögel U, Jacoby C, Heil M, Schaper W, Schrader J: Lack of ecto-5'-nucleotidase (CD73) promotes arteriogenesis. Cardiovasc Res 2013, 97:88-96. 10.1093/cvr/cvs286
39. Umapathy NS, Fan Z, Zemskov EA, Alieva IB, Black SM, Verin AD: Molecular mechanisms involved in adenosine-induced endothelial cell barrier enhancement. Vascul Pharmacol 2010, 52:199-206. 10.1016/j.vph.2009.12.008
40. Blay J, White TD, Hoskin DW: The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine. Cancer Res 1997, 57:2602-2605.
41. Sadej R, Spychala J, Skladanowski AC: Ecto-5'-nucleotidase (eN, CD73) is coexpressed with metastasis promoting antigens in human melanoma cells. Nucleosides Nucleotides Nucleic Acids 2006, 25:1119-1123. 10.1080/15257770600894188
42. Wang H, Lee S, Lo Nigro C, Lattanzio L, Merlano M, Monteverde M, Matin R, Purdie K, Mladkova N, Bergamaschi D, Harwood C, Syed N, Szlosarek P, Briasoulis E, McHugh A, Thompson A, Evans A, Leigh I, Fleming C, Inman GJ, Hatzimichael E, Proby C, Crook T: NT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity. Br J Cancer 2012, 106:1446-1452. 10.1038/bjc.2012.95
43. Hattori F, Ohshima Y, Seki S, Tsukimoto M, Sato M, Takenouchi T, Suzuki A, Takai E, Kitani H, Harada H, Kojima S: Feasibility study of B16 melanoma therapy using oxidized ATP to target purinergic receptor P2X7. Eur J Pharmacol 2012, 695:20-26. 10.1016/j.ejphar.2012.09.001
44. White N, Ryten M, Clayton E, Butler P, Burnstock G: P2Y purinergic receptors regulate the growth of human melanomas. Cancer Lett 2005, 224:81-91. 10.1016/j.canlet.2004.11.027